1. Torre LA, Siegel RL, Ward EM et al. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomark- ers Prev 2016;25:16–27.
2. Wang SS, Sherman ME, Hildesheim A et al. Cervical adenocarci- noma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004;100:1035–44.
3. Nataional Cancer Comprehensive Network. NCCN Guidelines: Cervical Cancer version 4.2019. 2019.
4. Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: A unique cervical cancer. Gynecol Oncol 2010;116:140–6.
5. Chen R-J, Lin Y-H, Chen C-A et al. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 1999;73:184–90.
6. Rose PG, Java JJ, Whitney CW et al. Locally advanced adenocar- cinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic oncol- ogy group trials of cisplatin-based chemoradiation. Gynecol Oncol 2014;135:208–12.
7. Lee J-Y, Kim YT, Kim S et al. Prognosis of cervical cancer in the era of concurrent Chemoradiation from National Database in Korea: A comparison between squamous cell carcinoma and adenocarcinoma. PLoS One 2015;10:e0144887.
8. Yokoi E, Mabuchi S, Takahashi R et al. Impact of histological subtype on survival in patients with locally advanced cervical can- cer that were treated with definitive radiotherapy: Adenocarcino- ma/adenosquamous carcinoma versus squamous cell carcinoma. J Gynecol Oncol 2017;28:e19.
9. Gadducci A, Guerrieri ME, Cosio S. Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clini- cal outcome and prognostic variables. Crit Rev Oncol Hematol 2019;135:103–14.
10. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960–4.
11. Suzuki Y, Mimura K, Yoshimoto Y et al. Immunogenic tumor cell death induced by Chemoradiotherapy in patients with Esophageal squamous cell carcinoma. Cancer Res 2012;72:3967–76.
12. Yoshimoto Y, Suzuki Y, Mimura K et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One 2014;9:e92572.
13. Nakano T, Oka K, Takahashi T et al. Roles of langerhans’ cells and T-lymphocytes infiltrating cancer tissues in patients treated by radiation therapy for cervical cancer. Cancer 1992;70: 2839–44.
14. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563–7.
15. Enwere EK, Kornaga EN, Dean M et al. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol 2017;1:1–10.
16. Reddy OL, Shintaku PI, Moatamed NA. Programmed death- ligand 1 (PD-L1) is expressed in a significant number of the uter- ine cervical carcinomas. Diagn Pathol 2017;12:1–11.
17. Mezache L, Paniccia B, Nyinawabera A et al. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol 2015;28:1594–602.
18. Heeren AM, Punt S, Bleeker MC et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carci- noma and adenocarcinoma of the cervix. Mod Pathol 2016;29: 753–63.
19. Kurman RJ, Carcangiu ML, Herrington CS et al. WHO Classifica- tion of Tumors of Female Reproductive Organs, 4th edn. Lyon: WHO Press, 2014.
20. Kojima A, Mikami Y, Sudo T et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocar- cinoma of the uterine cervix. Am J Surg Pathol 2007;31:664–72.
21. Karamurzin YS, Kiyokawa T, Parkash V et al. Gastric-type endo- cervical adenocarcinoma: An aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol 2015;39:1449–57.
22. Nishio S, Mikami Y, Tokunaga H et al. Analysis of gastric-type mucinous carcinoma of the uterine cervix — An aggressive tumor with a poor prognosis: A multi-institutional study. Gynecol Oncol 2019;153:13–9.
23. Okame S, Kojima A, Teramoto N et al. Type C2 radical hysterec- tomy may improve outcomes of locally advanced mucinous ade- nocarcinoma of the uterine cervix. IntJ Clin Oncol 2016;21:723–9.
24. Baalbergen A, Ewing-Graham PC, Hop WCJ et al. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 2004;92:262–7.
25. Nakano T, Arai T, Morita S et al. Radiation therapy alone for adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995;32:1331–6.
26. Wang J, Yu M, Guan S et al. Prognostic significance of PD-L1 in solid tumors: An updated meta-analysis. Medicine (Baltimore) 2017;96:e6369.
27. Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemora- diotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377:1919–29.
28. Meng Y, Liang H, Hu J et al. PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer 2018;9:2938–45.
29. Sato H, Niimi A, Yasuhara T et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 2017;8:1751.
30. Jordanova ES, Gorter A, Ayachi O et al. Human leukocyte anti- gen class I, MHC class I chain-related molecule a, and CD8+/ regulatory T-cell ratio: Which variable determines survival of cer- vical cancer patients? Clin Cancer Res 2008;14:2028–35.
31. Komdeur FL, Prins TM, van de Wall S et al. CD103+ tumor- infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology 2017;6:1–14.
32. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother cancer 2016;4:51.